As reported by Acorda at the JPM meeting in SF 2017 Ampyra Sales: $542 million 2018 Ampyra Sales (projected): $330-$350 million 2018 Ampyra sales decrease: 35% to 39%, Loss of approximately $200 million in sales These projections represent 6 months of generic sales for 2018 (July 2018 generic launch). Sales Projections (not reported by Acorda) 2019 Ampyra sales with generics for a full year. Further generic impact, after 12 months, results in a 70% to 80% loss of market share vs. peak sales of $542. Marketshare of 20% to 30% with sales of $108 million to $162 million. Sales loss of between $379 and $433 million. Reference: Journal of Chemical & Engineering News Vol 92, Issue 39, pages 8-16 September 2014 Title: 30 Years of Generics By: Ann M. Thayer "For drugs with sales great than $250 million per year, the average market share for a brand name drug, after 12 months of generics, is 11%". That is a loss of 89% marke share points. The above 2019 projections are more conservative that the numbers stated in the reference. If you stay with us at Acorda or if you decide to leave is your choice. Just look at the real facts before you decide.
Mr. 94% Glassdoor is about to have the glass broken. Inappropriate past behavior is going to come back into the light. #MeToo
********************** The OP has seriously obfuscated the facts. The projected degeneration in sales volume of Ampyra is much less than posted. Moreover we look forward to a commensurate uptick with intro of Inbrija, now projected for NLT August. The Wall Street analysts see this as a seamless transition, hence hedge fund investing in ACOR is thru the roof !! We need rank & file to support our Leadership 1000% as are on the cusp of even greater wins ! Go Go Go Acordians ! **********************
This is BS posting - without actual facts, you are spreading vicious gossips to ruin a reputation. Facts and Legal action - if you have the gonads. Otherwise, is just lies.
So you are cherry picking the highest estimate on Inbrija when consensus view is only $317m at peak year?! It’s one thing to be optimistic, another to be completely delusional.
both terms have been used extensively by Leadership; although the latter is also an instrument and could cause confusion...
What is “NLT August”? The PDUFA date for Inbrija is October 5. If it’s a one-cycle review with no major amendments (fat chance!), the earliest it could be on the shelves is mid to late October, more like December. But it will take more than one cycle to get it approved, as senior leadership well knows.
NLT August should have been more explicit: it means 'No Later Than August 2019'. Sorry for the confusion. 'NLT' is commonly used in Leadership in Project and Program Schedules.
Acorda agrees to enter agreement with Scopia that includes bringing two from Scopia capital to the board this week! Don’t forget this is the letter from Scopia last August: We are writing this letter to communicate our desire for management and the Board of Directors (the “Board”) to pursue an immediate review of all strategic alternatives, including a sale of the Company.We admire the business that you have built since founding the Company over 20 years ago. The Company raised $850M in capital to develop Ampyra, add commercial infrastructure and acquire pipeline assets. Unfortunately, today the Company is only valued at $1.2B by the public markets.While we have been supportive of the Company’s strategy to this point, we believe it is now time to sell the Company. Had the Company prevailed in the Ampyra litigation, Acorda would have been a unique company with a path to $1B in revenues and significant standalone value. Unfortunately, the Company was unsuccessful, and it has now crossed the Rubicon. In 2018 the business will revert to burning cash with a levered balance sheet and no clear timeline to return to profitability. These are treacherous waters. At the same time, recent acquisitions of both Cynapsus ($624M) and NeuroDerm ($1.1B) speak to the strategic value of late stage assets in Parkinson’s disease. Acorda is a more valuable acquisition candidate than either of these companies.
Who ever posted this is working agin Leadership and should be ashamed. We love our CEO and his Team !! There is NO - repeat NO - repeat NO - plans to sell out this great company !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
